Can something as good as Botox get even better?
Revance, Bonti and Evolus, three California biotechnology companies, are counting on it!
Aside from Galderma’s Dysport and Merz’s Xeomin, three new Botox offspring are about to hit the market. First up is Jeauveau by Evolus which received FDA approval on February 1, 2019. “European and Canadian studies showed a 4.4% statistical superiority of Jeauveau to Botox.” Next will likely be RT002 which promises a longer duration of action than Botox (about 6 months). And, finally, EB-001A offers a short onset of action (within 24 hours), and an associated shorter duration of action (one month instead of 3+ months) making it ideal for first time users, of for scar optimization after surgery.
Are you a member of the “newer is better” team or are do you belong to the “if it ain’t broke, don’t fix it” group? Undecided? Ask Dr. Yagoda which one is right for you. And, fingers crossed, perhaps more products will lead to more competitive pricing!
